Brief: BioInvent, Transgene Announce Collaboration And Supply Agreement With MSD
28/06/2022 07:23
June 28 (Reuters) - BioInvent International AB BINV.ST :
* BIOINVENT AND TRANSGENE ANNOUNCE CLINICAL TRIAL
COLLABORATION
AND SUPPLY AGREEMENT WITH MSD TO EVALUATE BT-001 IN COMBINATION
WITH KEYTRUDA®
* UNDER TERMS OF SUPPLY AGREEMENT, MSD WILL PROVIDE
PEMBROLIZUMAB
TO BE USED IN COMBINATION WITH BT-001 IN ONGOING PHASE 1/2A
CLINICAL TRIAL
* ANNOUNCED A CLINICAL TRIAL COLLABORATION AND SUPPLY
AGREEMENT
WITH MSD, A TRADENAME OF MERCK & CO., INC., RAHWAY, NJ., USA, TO
EVALUATE ONCOLYTIC VIRUS BT-001 IN COMBINATION WITH MSD'S
ANTI-PD-1 THERAPY KEYTRUDA® (PEMBROLIZUMAB) IN A PHASE 1/2A
CLINICAL TRIAL FOR TREATMENT OF PATIENTS WITH SOLID TUMORS
* THIS AGREEMENT WILL ALLOW US TO MOVE FURTHER ON CLINICAL
DEVELOPMENT OF OUR PROMISING CO-DEVELOPED ONCOLYTIC CANDIDATE
BT-001-TRANSGENE CEO
Source text for Eikon: ID:nMFN1CfCW1
Further company coverage: BINV.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))